Navigation Links
QRxPharma Initiates Second Comparative Study for MoxDuo(TM) IR Dual-Opioid(TM) Pain Therapy
Date:2/19/2009

eplacement will be treated every four to six hours over a 48-hour period. The study is targeted to enroll a total of 45 patients at three US clinical research sites.

Primary objectives of the study include: (1) comparing the analgesic efficacy and safety profile of MoxDuo(TM) IR against control groups of patients receiving Percocet(R), a frequently used opioid for the treatment of pain, and (2) comparing MoxDuo(TM) IR against the present standard use of intravenous (IV) morphine in patients who self-control their pain relief using "patient controlled analgesia" (PCA). Data from these studies will further augment our knowledge about how to optimize the design and implementation of our pending pivotal Phase 3 studies in this patient population.

MoxDuo(TM) IR is the first patented analgesic product in the world that consists of two opioid drugs (a fixed ratio of morphine and oxycodone). While many analgesic combination drugs exist - such as Percocet(R) , which contains an opioid (oxycodone) combined with acetaminophen (like Tylenol(R)), such products are typically used for controlling mild to moderate pain. MoxDuo(TM) IR, however, is intended for the treatment of moderate to severe pain such as the acute pain that follows surgery. In six clinical trials conducted to date, data indicate that QRxPharma's patented combination of morphine plus oxycodone works synergistically to increase analgesia while diminishing the usual side effects of opioids. MoxDuo(TM) IR leads our development of a portfolio of dual-opioids(TM), including intravenous (MoxDuo(TM) IV) and sustained release (MoxDuo(TM) CR) formulations.

Based on the Company's July 2008 FDA meeting, final Phase 3 studies for MoxDuo(TM) IR will include a "combination rule" trial in patients experiencing post-surgery (bunionectomy) pain that compares MoxDuo(TM) IR against morphine alone and oxycodone alone, and a placebo-controlled study of the effectiveness of
'/>"/>

SOURCE QRxPharma Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. QRxPharma Initiates Comparative Study for MoxDuoIR(TM) Dual-Opioid(TM) Pain Therapy
2. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
3. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
4. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
5. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
6. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
7. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
8. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
9. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
10. Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
11. Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... IL (PRWEB) January 15, 2014 Look ... find hard-working items for the lab, from fluid handling ... Guaranteed-in-Stock (GIS)—ready to ship when you order. , ... Peristaltic Pumps , from the L/S® model for precise ...
(Date:1/15/2014)... ­ RedBrick Health , a fast-growing leader in ... that EmblemHealth , the New York ... providing the RedBrick Compass health assessment, combined with the ... its members. EmblemHealth is among the first health plans ...
(Date:1/15/2014)... January 15, 2014 More than 5 ... about 1 in 3 seniors will die with Alzheimer’s ... These jaw-dropping figures have shocked many Americans into looking ... help prevent these tragic age-related cognitive disorders. Jonathan Weisman, ...
(Date:1/15/2014)... 15, 2014 DTS Language Services, Inc ... Web Portal for Life Science organizations who need document translations. ... subject matter of their documents in advance with a selection ... time-to-delivery of translations, often a critical factor in clinical and ...
Breaking Biology Technology:Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2DTS Improves Efficiency for Life Science Document Translations 2
... " This Man Was Erroneously Convicted of Murder and a Wrong ... Right by Granting a Pardon" Giovanni Di Stefano, ... Secretary of State to pardon posthumously Dr. Hawley Harvey Crippen. In,a ... upon DNA, Di Stefano calls on the Secretary of State for,the ...
... BioMedical Enterprises, Inc.,(BME), a privately held medical ... technology, today announced that the U.S. Food and,Drug ... the,OSSpine(TM) for use in anterior fixation of the ... graft retention. The patent-pending,OSSpine(TM) builds on the extremity ...
... THE WOODLANDS, Texas, Oct. 22 Lexicon,Pharmaceuticals, Inc. (Nasdaq: ... results on Tuesday, October 30, 2007 after the financial ... discuss the,company,s results and provide financial guidance for the ... October 30, 2007. The dial-in number for the ...
Cached Biology Technology:BioMedical Enterprises, Inc. (BME) Receives FDA Clearance for Spine Use of Its Memory Metal Implants 2Lexicon to Report Third Quarter 2007 Financial Results on October 30, 2007 2
(Date:7/10/2014)... New research from The University of Texas Health ... GameKeep it Real (IYG), a health education program designed ... can significantly reduce dating violence behaviors among minority youth. ... Prevention, 10 percent of high school youth are victims ... more than 20 percent are victims of emotional dating ...
(Date:7/10/2014)... cutting-edge, innovative research on Alzheimer,s disease and the ... announced the recipients of new research grant awards, ... the District of Columbia, and five foreign countries. ... latest grants, BrightFocus has now provided more than ... The research projects funded this year reflect a ...
(Date:7/10/2014)... IRVINE, Calif. (July 10, 2014) Consuming a whole ... raw carrots significantly enhanced provitamin A carotenoid (alpha- and ... active form of vitamin A, according to new research ... . , Vitamin A is involved ... skin, immune function, and vision; and has antioxidant properties. ...
Breaking Biology News(10 mins):It's Your Game ... Keep It Real reduces dating violence among minority youth 2BrightFocus Foundation announces 55 new grantees in Alzheimer's and vision research 2BrightFocus Foundation announces 55 new grantees in Alzheimer's and vision research 3New research: Fresh avocado enhances absorption of essential nutrients for healthy living 2
... pathway whereby bacteria communicate with each other has been ... The discovery has important implications for efforts to cope ... Bacteria are known to communicate in nature primarily ... said Prof. Sigal Ben-Yehuda of the Institute for Medical ...
... microfluidic device may help clinicians improve a promising cancer ... fight such diseases as metastatic melanoma, non-Hodgkin,s lymphoma, chronic ... adoptive T cell transfer, has shown encouraging results in ... called T cells from a cancer patient, multiplying them ...
... have engineered bacteria to churn out a gasoline-like biofuel ... a breakthrough that could soon provide an affordable and ... this week in advance of publication in the journal ... Chang, assistant professor of chemistry at UC Berkeley, graduate ...
Cached Biology News:Researchers predict age of T cells to improve cancer treatment 2Researchers predict age of T cells to improve cancer treatment 3Turning bacteria into butanol biofuel factories 2Turning bacteria into butanol biofuel factories 3
...
... Distributed exclusively by BioLegend, the Quansys ... for multiplex analysis of cytokines/chemokines for human, ... Cytokine Array is a fully quantitative ELISA-based ... been absorbed to each well of a ...
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
... Pro260 reagents and supplies, for 10 ... sufficient to perform protein analysis with ... electrophoresis system. Supplied are 3 x ... Pro260 stain, 60 microliters Pro260 ladder ...
Biology Products: